Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026)
Nuvectis Pharma (NVCT) posted Accumulated Expenses of $36000.0 for Q1 2026, down 68.7% sequentially from $115000.0 in Q4 2025, and down 99.29% YoY from $5.0 million in Q1 2025.
Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Accumulated Expenses for 6 years, with the latest figure at $36000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 99.29% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36000.0 (down 99.29% YoY) and the FY2025 annual result came in at $115000.0, down 97.93% from the prior year.
- Accumulated Expenses declined to $36000.0 in Q1 2026 per NVCT's latest filing, from $115000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $5.6 million in Q4 2024 and troughed at $2000.0 in Q2 2025.
- A 5-year average of $1.9 million and a median of $863000.0 in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 2287.97% in 2024, then tumbled 99.94% in 2025.
- Over 5 years, Accumulated Expenses stood at $445000.0 in 2022, then jumped by 753.48% to $3.8 million in 2023, then surged by 46.29% to $5.6 million in 2024, then plunged by 97.93% to $115000.0 in 2025, then sank by 68.7% to $36000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $36000.0, $115000.0, and $65000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.63 Mn |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 5.56 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 445,000.00 |
| Sep 30, 2022 | 863,000.00 |
| Jun 30, 2022 | 790,000.00 |
| Mar 31, 2022 | 697,000.00 |
| Dec 31, 2021 | 142,000.00 |